| Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options under consideration. |
| Recommendations are limited to DMARDs approved by the US FDA for treatment of RA.                                                                |
| csDMARDs: hydroxychloroquine, sulfasalazine, methotrexate, leflunomide.                                                                         |